Minutes of extraordinary general meeting 2026

Multiconsult ASA shareholders approved the proposed merger with Rejlers AB at an extraordinary general meeting on 19 October 2026. The merger plan, dated 7 September 2026, names Multiconsult as the transferring company and Rejlers as the acquiring company; no transaction value or other terms were provided.

Analysis

The vote removes one execution hurdle for Rejlers, but its value to REJL.B depends on terms and remaining closing conditions—not the approval itself. With no consideration, exchange ratio, timetable, or synergy targets supplied, neither accretion nor dilution can be assessed; treat any immediate move as a reduction in deal uncertainty rather than evidence of improved earnings power.

Over 1–3 months, verify the merger conditions, regulatory and any other required approvals, expected closing date, and financing or share-issuance mechanics. If the combination closes, a broader engineering-consulting footprint could support cross-selling and improve utilization, but those benefits are hypotheses until management quantifies them. Integration demands or retention issues could instead distract delivery teams and weigh on margins. Competitors such as Sweco and AFRY could face a stronger bid competitor, though any impact is likely gradual and dependent on actual execution.

The contrarian point: unanimous progress on a formal approval can look more decisive than it is economically. If the market already priced in shareholder support, the announcement may offer little incremental upside; the asymmetric risk is that unresolved terms or conditions reintroduce uncertainty. No standalone trade is justified on this release alone.

Key Decisions for Investors

• Keep REJL.B on a deal-monitoring list; do not add exposure solely on the vote. First obtain the merger terms, expected closing date, remaining conditions, and any share issuance or financing details.
• For the next 1–3 months, track formal closing-condition updates and management’s quantified synergy, integration-cost, and earnings-impact disclosures. Treat synergy claims as unverified until reflected in guidance or reported results.
• Falsification / risk trigger: reassess the positive de-risking view if a required approval is denied or delayed, the timetable slips, or disclosed consideration and integration costs imply materially weaker per-share economics than expected.